Catalent (CTLT) : Zacks Investment Research ranks Catalent (CTLT) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2.25, which indicates as a Buy.
Catalent (CTLT) : 5 investment research analysts covering Catalent (CTLT) have an average price target of $26.5 for the near short term. The highest target price given by the Brokerage Firm to the stock is $31 and the lowest target is $23 for the short term. Analysts expect the variance to be within $2.87 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Catalent (NYSE:CTLT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $25.10 and $25.03 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $25.43. The buying momentum continued till the end and the stock did not give up its gains. It closed at $25.34, notching a gain of 1.04% for the day. The total traded volume was 566,282 . The stock had closed at $25.08 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Walsh Matthew M, officer (See Remarks) of Catalent, Inc., had unloaded 21,197 shares at an average price of $28.85 in a transaction dated on May 27, 2016. The total value of the transaction was worth $611,533.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.